Explore the science behind the Revolution Platform.

Optimizing cfRNA Recovery from Liquid Biopsy for Downstream RNA Sequencing Webinar with nRichDX

Webinar

Organizations: GENEWIZ/Azenta and nRichDX

Dr. Nafiseh Jafari and Kamran Syed introduce the nRichDX liquid biopsy sample prep system and its role in improving downstream assay sensitivity for early-stage cancer, MRD, and rare variant detection.

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Proceedings of the National Academy of Sciences (PNAS) , 123(16), e2537987123. https://doi.org/10.1073/pnas.2537987123

Authors: Wang, Y., et al., Johns Hopkins University School of Medicine

The study demonstrates the potential of plasma cell-free DNA to support longitudinal monitoring of disease burden in patients with acute myeloid leukemia (AML) undergoing bone marrow transplantation.

Cell-Free RNA Urogenital Cancer Biomarker Detection from Urine

American Association for Cancer Research 2026 Annual Meeting

Organizations: GENEWIZ/Azenta and nRichDX

This poster demonstrates the efficient recovery and sequencing of cell-free RNA (cfRNA) from urine samples using the nRichDX Revolution Plus System for applications in urogenital cancer biomarker detection.

Analytical Performance of Magnetic Bead–Based cfDNA Extraction with a Low-Input Targeted DNA Enrichment

American Association for Cancer Research 2026 Annual Meeting

Organizations: Agilent and nRichDX

This poster demonstrates the performance of the nRichDX Revolution cfDNA Max 20 Kit in low-input targeted DNA sequencing workflows. Using plasma samples, the study showed improved recovery of library-eligible cfDNA, greater molecular detection, and more uniform sequencing coverage compared to a commonly used magne…

RNA Recovery from 1-20mL Inputs Enables Sensitive KRAS G12V Detection in a Liquid Biopsy Model

American Association for Cancer Research 2026 Annual Meeting

Organizations: nRichDX

This poster demonstrates the ability of the nRichDX Revolution cfTNA Max 20 Kit to recover circulating RNA from plasma inputs ranging from 1 mL to 20 mL for sensitive mutation detection applications.

Automated high-volume cfDNA extraction on Hamilton STAR achieves analytical equivalence to manual nRichDX Revolution® protocol while enabling 96-sample batch processing

American Association for Cancer Research 2026 Annual Meeting

Organizations: nRichDX

This poster demonstrates the successful automation of the nRichDX Revolution cfDNA extraction workflow on the Hamilton STAR liquid handling platform for high-throughput liquid biopsy applications.

Enhanced sensitivity and scalability in liquid biopsy through integrated high-volume cfDNA extraction and droplet digital PCR mutation detection

American Association for Cancer Research 2026 Annual Meeting

Organizations: Bio-Rad nRichDX

This poster demonstrates the combined use of the nRichDX Revolution cfDNA Max 20 Kit and Bio-Rad Droplet Digital PCR (ddPCR) for sensitive detection of low-frequency mutations in liquid biopsy samples.

Efficient Recovery of Cell-Free DNA from Synthetic Cerebrospinal Fluid Enables Sensitive Molecular Profiling in Brain Cancer

AACR Special Conference in Cancer Research: Brain Cancer

Organizations: nRichDX

This poster shows that efficient, reproducible extraction of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF)-like samples enables sensitive molecular profiling for brain cancer applications.

Urine Liquid Biopsy for Kidney Cancer: High-Volume cfRNA Extraction Enhances Detection of Renal Cancer Biomarkers for Early Detection

AACR Special Conference in Cancer Research: Innovations in Kidney Cancer Research...

Organizations: nRichDX and Anchor Molecular

This poster demonstrates that urine is a promising noninvasive biofluid for kidney cancer detection, but traditional workflows are limited by low cfRNA abundance and small input volumes. It evaluates a high-volume (up to 20 mL) cfRNA extraction workflow using the nRichDX Revolution system to improve analytical sen…

Comparative Evaluation of Whole Urine and Pellet-Based Extraction Workflows for Urine Liquid Biopsy

10th Liquid Biopsy for Precision Oncology Summit

Organizations: nRichDX

This poster describes a direct single-extraction workflow for processing of high volumes of whole urine using the nRichDX Revolution Sample Prep System. The method captures nucleic acids from both the cell-associated and cell-free fractions in one workflow.

Accurate and reliable detection of clonal hematopoiesis in plasma cell-free DNA

Blood advances (Journal of the ASH) , 10 (2), 413–417. https://doi.org/10.1182/bloodadvances.2025017293

Authors: Parker, A. C., et al., Vanderbilt University School of Medicine

The study shows that plasma cfDNA can reliably detect and quantify clonal hematopoiesis (CHIP) with strong concordance to whole blood DNA, enabled in part by the nRichDX Revolution cfDNA extraction workflow, which consistently produced sufficient, high-quality cfDNA (≥1.76 ng/µL from 4 mL plasma) for deep sequenci…

Breast Cancer Mutation Detection via Liquid Biopsy Using cfDNA from 50 mL Urine Samples

San Antonio Breast Cancer Symposium (SABCS) 2025

Organizations: nRichDX and Anchor Molecular

This poster shows that 50 mL urine can serve as a stable, non-invasive liquid biopsy source for breast cancer mutation detection. Using contrived urine samples preserved with Tris-EDTA, Streck, or UAS and stored up to 72 hours at room temperature, cfDNA extracted with the nRichDX Revolution Max 50 cfDNA Kit suppor…

Quantitative Comparison of cfRNA and cDNA Recovery From Plasma and Cell Culture Media Using Two Commercial Extraction Platforms

Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo

Organizations: nRichDX and UCSC (Kim Lab)

This poster compared extraction of cfRNA and cDNA derived from 40 mL cultured H358 non-small cell lung cancer cells and 3 mL of human plasma. Side-by-side extraction between the nRichDX cfTNA Max 20 Kit and the Qiagen exoRNeasy kit was performed following the manufacturer's protocols.

High-Volume (50 mL) Urine Input Outperforms Lower Volumes in Liquid Biopsy cfDNA Detection of Low-Frequency Mutations

Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo

Organizations: nRichDX

This poster compared detection via qPCR of low-frequency KRASG12V derived from 50 mL and smaller volumes of urine using the nRichDX Revolution cfDNA Max 50 Kit - which unlike other methods is capable of processing 50 mL of urine in a single extraction.

Preliminary Analysis of cfDNA Dynamics in Pediatric CNS Tumors via CSF Liquid Biopsy

Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo

Organizations: nRichDX and collaborators at Nationwide Children's Hospital

This poster described extraction and analysis of cerebrospinal fluid (CSF) derived from pediatric patients using the nRichDX cfDNA Max 20 Kit followed by quantification and characterization by Qubit and TapeStation.

Evaluation of cfDNA Mutation Recovery from Widest Sample Volume Range using Magnetic Bead-Based Extraction

Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo

Organizations: nRichDX and Sens-ID

This poster described preparation of nucleosome-sized ctDNA (n-ctDNA generated from tumor/normal-matched breast cancer cell lines using a proprietary method from Sens-ID followed by cfDNA extraction using nRichDX's cfDNA Max 20 Kit.

High Volume cfDNA Extraction Enables Rare Variant Recovery in Liquid Biopsy for Early Cancer Detection

International Society of Liquid Biopsy (ISLB) 7th Annual Meeting

Organizations: nRichDX

This poster describes how high-volume cfDNA extraction improves the recovery and detection of rare circulating tumor DNA (ctDNA) variants for liquid biopsy applications, particularly in low-yield samples.

Current Perspectives on RNA Liquid Biopsy: Impact of RNA Extraction on Assay Performance (on-demand video)

Webinar

Organizations: nRichDX

This on-demand webinar features keynote presenter Daniel Kim, PhD, Assistant Professor, UC Santa Cruz and concludes with a Q&A panel session with the webinar attendees at the live event held 16 October 2025. Dr.

cfRNA Cryptic Intron Identification from Liquid Biopsy Samples

American Society of Human Genetics (ASHG) 2025 Annual Meeting

Organizations: GENEWIZ/Azenta and nRichDX

This poster compared cfRNA extraction from plasma from 4 ALS patients and 1 healthy control from the following kits: Qiagen miRNeasy Serum/Plasma Advanced Kit, Qiagen QIAamp ccfRNA Kit, Zymo's Quick-cfRNA Serum and Plasma Kit, and the nRichDX Revolution cfTNA Kit followed by library prep, then sequencing and analy…

Full-Length Clonal Immunoglobulin Rearrangements in cfDNA: Improved Recovery and Sequencing Author: Xian, R. R., et al., Johns Hopkins University School of Medicine

Clinical Chemistry (Journal) , 71 (8), 896–907. https://doi.org/10.1093/clinchem/hvaf064 ; link to abstract: https://pubmed.ncbi.nlm.nih.gov/40415574/

This article compares the extraction of cell-free DNA (cfDNA) from plasma using two different kits: the paramagnetic bead-based nRichDX Revolution cfDNA Max 20 Kit and the column-based Qiagen QIAamp Circulating Nucleic Acid Kit.

Standardized Workflow and Analytical Validation of Cell-Free DNA Extraction for Liquid Biopsy Using a Magnetic Bead-Based Cartridge System Author: Sathyanarayana, S. et al., The Laboratory for Clinical Genomics and Advanced Technology, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center

Cells 2025 , 14 (14), 1062; https://doi.org/10.3390/cells14141062

This article presents a comprehensive analytical validation of the nRichDX Revolution System with a focus on assessing its efficiency, reproducibility, and compatibility with downstream molecular applications.

Enhancing Sensitivity of cfDNA Copy Number by Increasing Plasma Sample Volume

International Society of Liquid Biopsy (ISLB) 6th Annual Congress

Organizations: nRichDX

This poster describes and characterizes increased cfDNA yield from extractions of larger input sample volumes of plasma and increased assay sensitivity using the nRichDX Revolution cfDNA Max 20 Kit. Extracting cfDNA from small-volume plasma samples poses challenges in achieving sufficient actionable cfDNA.

The Mutational Landscape of Circulating Tumor Cells in Pancreatic Cancer

Association for Molecular Pathology (AMP) 2024 Annual Meeting

Organizations: Dartmouth Hitchcock Medical Center

This poster describes isolation of CTCs from pancreatic cancer patients post surgery and adjuvant therapy using the nRichDX Revolution Sample Prep System and two nRichDX kits: the Revolution CTC Isolation Kit (Epithelial Origin) and the Revolution cfDNA Max 20 Kit followed by NGS library prep and Whole Exome Seque…

Clinical Validation of Cell-free DNA (cfDNA) Extraction from Whole Blood Plasma using the nRichDX ® Revolution Max 20 Kit and Sample Prep System

Association for Molecular Pathology (AMP) 2024 Annual Meeting

Organizations: Dartmouth Hitchcock Medical Center

This poster describes clinical validation of the nRichDX Revolution Sample Prep System and extraction of cfDNA from blood plasma using the nRichDX Revolution Max 20 Kit. cfDNA was quality control analyzed and cfDNA stability determined on the Agilent TapeStation, followed by stability testing of isolated cfDNA and…

Enhanced Extraction and Preservation of Circulating Cell-Free RNA from 50 mL Cell-Free Urine

Association for Molecular Pathology (AMP) 30th Annual Meeting and Expo

Organizations: nRichDX and Agilent

This poster describes the extraction of 12, 50 mL urine samples spiked with free RNA extracted from LnCAP cells containing the PTEN mutation. Parallel extractions were performed using the Revolution cfTNA Max 50 Kit and the Zymo ZR Urine RNA Isolation Kit and the Norgen Urine Cell-free Circulating and Viral Nuclei…

Enhanced cell-free RNA (cfRNA) recovery for liquid biopsy applications: Comparative analysis using controlled RNA samples for early and advanced cancer detection

AACR Special Conference on Liquid Biopsy

Organizations: nRichDX

This poster describes extraction of cfRNA from plasma using the nRichDX Revolution cfTNA Kit as compared to Qiagen's QIAamp extraction on the QIAvac vacuum manifold method. Workflow and performance characteristics of each method are compared.

Integrated Liquid Biopsy for Prostate Cancer: Capturing Circulating Tumor Cells and Urinary Cell-Free Total Nucleic Acid

Cancer Genomics Consortium (CGC) 2024 15th Annual Meeting

Organizations: Anchor Molecular and nRichDX

This poster describes the extraction of LNCaP prostate cancer cells from whole blood and the TMPRSS2-ERG prostate cancer RNA fusion as circulating cell-free nucleic acid from urine using nRichDX's Revolution CTC Enrichment (Epithelial) Kit and the Revolution cfTNA Max 20 Kit.

Current Perspectives on Pre-Analytical Variables that Impact Liquid Biopsy Test Sensitivity (video)

Webinar

Organizations: nRichDX

This webinar features keynote presenter Tina Lockwood, PhD.; Division Head, Genetics and Solid Tumors at the University of Washington School of Medicine and concludes with a Q&A session with the webinar attendees at the live event.

Unraveling the Link Between Total cfDNA Quantified by Agilent TapeStation Cell-free DNA ScreenTape and Actionable cfDNA Molecules Measured on Downstream Assays

Association for Molecular Pathology (AMP) Europe Congress 2024

Organizations: Agilent and nRichDX

This poster aims to show the correlation between total cfDNA quantified by Agilent Cell-free DNA ScreenTape assay and the detection of actionable cfDNA molecules through qPCR. nRichDX Revolution Sample Prep demonstrated high extraction efficiency of cfDNA at 89% across 38 samples.

Exploring Liquid Biopsy for the Detection of Bladder Cancer: Unraveling RNA Fusions

AACR Special Conference in Cancer Research: Bladder Cancer: Transforming the Field

Organizations: Anchor Molecular and nRichDX

This poster describes research using whole urine samples in a liquid biopsy context for the detection of the RNA fusions specifically associated with bladder cancer: ETV6-NTRK3 and PRCC-TFE3 .

VIDEO: Q&A of Poster Titled, "Exploring Liquid Biopsy for the Detection of Bladder Cancer: Unraveling RNA Fusions"

Online posting

Organizations: Anchor Molecular and nRichDX

In this brief video Q&A, Dr. Nafiseh Jafari, CSO of nRichDX, discusses the objectives of this study, its methods, and next steps.

Enhanced DNA Extraction from Large Whole Urine Volumes: Implications for Prostate Cancer Detection

New Frontiers in Liquid Biopsies: Data, Technology and Translational Potential (NIH)

Organizations: nRichDX

This poster describes extraction of cfDNA from urine using the nRichDX Revolution cfDNA Max 20 Kit as compared to the Zymo ® Quick-DNA Kit. Results demonstrate higher yield of actionable DNA molecules evidenced by lower Ct value using the PTEN mutation - a tumor suppressor gene frequently altered in prostate cance…

Enhancing urine-based cfDNA detection for prostate cancer diagnosis through increased input volume

American Association for Cancer Research 2024 Annual Meeting

Organizations: Agilent and nRichDX

This poster, jointly presented with Agilent, describes sensitive cfDNA detection using the enhanced nRicher Cartridge input urine volume in a single extraction. TapeStation tracings demonstrated proportionally increasing cfDNA yield with increasing sample volume when using the nRichDX Revolution system.

First-void urine as a non-invasive proxy for plasma in prostate cancer-related liquid biopsy applications.

American Association for Cancer Research 2024 Annual Meeting

Organizations: Novosanis and nRichDX

This poster, jointly presented with Novosanis, describes a comparison of first-void urine samples with plasma samples. Further investigations are needed to evaluate clinical samples and biomarkers to establish a robust correlation between cfDNA levels and cancer types and stages.

Achieving sensitivity of 0.1% variant allele frequency (VAF) in plasma and urine with the nRichDX revolution sample prep system evaluated on the MassARRAY ® system

American Association for Cancer Research 2024 Annual Meeting

Organizations: Agena Bioscience and nRichDX

This poster, jointly presented with Agena Bioscience, describes sensitive variant allele frequency detection of 0.1% on the Agena MassARRAY platform when coupled with high-yield analyte extraction from both plasma and urine samples using Revolution Sample Prep.

Assessment of Cell-free DNA (cfDNA) Extraction Using the nRichDX Revolution Sample Prep System from Plasma, Urine, and Pancreatic Cyst Fluid

Association for Molecular Pathology (AMP) 2023 Annual Meeting

Organizations: Dartmouth Hitchcock Medical Center

This poster from the Tsongalis Lab at Dartmouth Hitchcock describes cfDNA extraction and analysis using the nRichDX Revolution System from three different human clinical sample types used in liquid biopsy: blood plasma, urine, and pancreatic cyst fluid.

Unraveling the Link Between Total cfDNA Quantified by Agilent TapeStation Cell-free DNA ScreenTape and Actionable cfDNA Molecules Measured on Downstream Assays

Association for Molecular Pathology (AMP) 2023 Annual Meeting

Organizations: Agilent and nRichDX

This poster, jointly presented with Agilent Technologies, describes high-quality cfDNA extraction using the nRichDX Revolution Sample Prep System followed by analysis using the Agilent TapeStation ScreenTape. Actionable cfDNA molecules as compared to artifacts are described.

Back-to-Back Presentations (video): nRichDX Revolution Sample Prep System for Liquid Biopsy - Overview and Performance Data (Jafari) Improving the Efficiency of Liquid Biopsy Extraction Using the nRichDX Revolution System (Sathyanarayana)

Association for Molecular Pathology (AMP) 2023 Annual Meeting - Innovation Spotlight Stage 2

Organizations: Dartmouth Hitchcock Medical Center, nRichDX

In this video, Nafiseh Jafari, PhD, CSO of nRichDX presents an overview of the Revolution Sample Prep System for liquid biopsy and Shiva Sathyanarayana, PhD from the Tsongalis Lab at Dartmouth Hitchcock Medical Center, provide an overview of Liquid Biopsy and the Revolution Sample Prep System from nRichDX.

Pre-analytical Considerations for Minimum Residual Disease Detection by Next-Generation Sequencing (video)

Webinar

Organizations: Agilent, nRichDX, Strata Oncology

In this webinar, Scott Tomlins, MD, PhD and Travis Reeder from Strata Oncology, will highlight the importance of cfDNA yield and purity using the Revolution Sample Prep System from nRichDX for cfDNA extraction as well as reliable pre-analytical quality control with the Agilent Cell-free DNA ScreenTape assay and th…

Extraction of Multiple Analytes in Liquid Biopsy May Improve the Diagnosis of Breast Cancer

Cancer Genomics Consortium (CGC) 2023 14th Annual Meeting

Organizations: nRichDX

This poster describes the extraction of analytes from two fractions from a single whole blood sample - cfDNA from the plasma fraction, and CTCs enrichment from the sample's buffy coat fraction - using the Revolution cfTNA Max 20 Kit and nRichDX's new Revolution CTC Enrichment (Epithelial) Kit.

Current Perspectives on Liquid Biopsy Technologies (video)

Webinar

Organizations: UKE, nRichDX

This webinar features keynote presenter Klaus Pantel, MD, PhD. Chairman of the Institute of Tumour Biology, University Medical Center Hamburg-Eppendorf, and Founder and Chairman of the European Liquid Biopsy Society (ELBS).

The nRichDX Revolution Sample Prep System ™ enables recovery of more amplifiable copies and more cancer fraction detection from cfDNA as evaluated on the MassARRAY ® System

American Association for Cancer Research (AACR) Annual Meeting 2023

Organizations: Agena Bioscience, nRichDX

This poster demonstrates the Revolution System's ability to extract more amplifiable copies of cfDNA and ctDNA biomarkers from plasma samples of 5 mL and 20 mL as compared to a leading competitor's kit.

Method Comparison of Commercially Available cfDNA Extraction Products for Minimum Residual Disease Next Generation Sequencing

Molecular & Precision Medicine (TRI-CON) 2023 Annual Meeting

Organizations: Strata Oncology

This poster is a side-by-side comparison of the Revolution System's cfDNA Kit with several other methods. cfDNA was extracted and quality metrics and cfDNA yields were compared. Results indicate the Revolution Kit provided higher cfDNA yields and lower gDNA contamination as compared to other methods.

Detection of Somatic Variants in Breast Cancer from Large Volumes of Plasma Using the nRichDX Revolution System

Molecular & Precision Medicine (TRI-CON) 2023 Annual Meeting

Organizations: nRichDX

This poster demonstrates the Revolution cfDNA isolation kit's ability to extract circulating cell-free deoxyribonucleic acid (cfDNA) from plasma samples of up to 20 mL in a single extraction. cfDNA total yield was measured via Qubit and characterized by TapeStation, and Ct values for a well-characterized breast ca…

Higher Total RNA Yields and Sequenceable RNA is Attainable Using the nRichDX Revolution Sample Prep System Total Nucleic Acid Isolation Kit

Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo

Organizations: nRichDX

This poster demonstrates the Revolution cell-free Total Nucleic Acid Isolation Kit's ability to extract circulating cell-free total nucleic acid (cfNA) including circulating free RNA (cfRNA) from plasma samples of up to 20 mL in a single extraction.

Colli-Pee ® UAS™ Combined with nRichDX Revolution System™, a Promising Urinary Cell-free DNA Collection, Preservation and Extraction Workflow

Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo

Organizations: University of Antwerp, nRichDX, Novosanis, DNA Genotek

This poster demonstrates the compatibility of the Colli-Pee and UAS urine collection system from Novosanis with the nRichDX Revolution Sample Prep System for extraction of cfDNA from up to 20 mL of urine in a single extraction. cfDNA yield, purity, and other factors were compared with other sample prep methods.

Current Perspectives - Molecular Profiling of Urine for Prostate Cancer Diagnosis: Opportunities and Challenges (video)

Webinar

Organizations: University of Michigan, nRichDX, Novosanis

This joint webinar with nRichDX partner Novosanis covers current opportunities and challenges of urine as a sample type for molecular profiling of prostate cancer from Keynote Presenter, Dr. Simpa Salami, Assistant Professor of Urology and Co-Director of the University of Michigan's Liquid Biopsy Core Laboratory.

The Revolution Sample Prep System for Liquid Biopsy Applications (video)

Cancer Genomics Consortium (CGC) 2022 13th Annual Meeting

Organizations: nRichDX

This video provides a brief introduction to the Revolution Sample Prep System from Nafiseh Jafari, PhD of nRichDX.

Higher cfRNA Recovery and Precision from Large Urine Sample Volumes Using the nRichDX Revolution Sample Prep System

Cancer Genomics Consortium (CGC) 2022 13th Annual Meeting

Organizations: nRichDX

This poster demonstrates the Revolution Sample Prep System's ability to extract circulating free total nucleic acid (cfNA) and circulating free RNA (cfRNA) from urine samples of up to 20 mL in a single extraction.

Higher cfDNA Recovery and Precision from Large Urine Sample Volumes Using the nRichDX Revolution Sample Prep System

Cancer Genomics Consortium (CGC) 2022 13th Annual Meeting

Organizations: nRichDX

This poster demonstrates the Revolution Sample Prep System's compatibility with the Novosanis ® Colli-Pee ® sample collection and stabilization system for recovery of cfDNA from urine samples of up to 20 mL in a single extraction.

MinION Nanopore Sequencing of cell-free DNA (cfDNA) and cell-free RNA (cfRNA) extracted from human plasma using nRichDX Revolution System

Association for Molecular Pathology (AMP) 2021 Annual Meeting

Organizations: nRichDX

This poster demonstrates the Revolution Sample Prep System's compatibility with Oxford Nanopore Technologies' MinION sequencing device for NGS sequencing of cfDNA and cfRNA.

Semi-Automated High Yield cfDNA Extraction Using nRichDX Revolution Sample Prep System on Eppendorf epMotion for Liquid Biopsy Development

Association for Molecular Pathology (AMP) 2021 Annual Meeting

Organizations: nRichDX

This poster describes the Semi-Automated Workflow of Revolution Sample Prep on the Eppendorf epMotion 5073 liquid handler.

nRichDX Revolution Instrument and cfDNA isolation Kit for Extraction of cfDNA from Large Plasma and Urine Sample Volumes Improves Yield of Rare Targets

Association for Molecular Pathology (AMP) 2019 Annual Meeting

Organizations: nRichDX

This poster introduces the Revolution Sample Prep System for extraction of cfDNA from plasma and urine samples as compared to a competing sample prep kit.

Assessment of the nRichDX Revolution Instrument and Isolation Kit for cell-free DNA Extraction from Liquid Biopsy

Association for Molecular Pathology (AMP) 2019 Annual Meeting

Organizations: Dartmouth Hitchcock

This poster from the laboratory of Dr. Gregory Tsongalis evaluates the nRichDX Revolution Sample Prep System for extraction of cfDNA.